Search PubMed⌕ Search

Biomedical subjects

J Bilski

Publications and source records attributed to J Bilski.

52 records · Page 3Linked to original sources
PubMed1986

Relationships between duodenal motility and pancreatic secretion in fasted and fed dogs.

A relationship between duodenal myoelectric or motor activity and exocrine pancreatic secretion as well as plasma gut hormone levels has been investigated in fasted dogs, fed dogs, and dogs that were stimulated with exogenous gut hormones. Pancreatic secretion showed typical periodicity in phase with the myoelectric or motor activity of the duodenum. Fasting pancreatic bicarbonate and protein secretion reached peaks during phase III of the interdigestive migrating motor complex (MMC) cycle that were significantly larger than nadir levels occurring during phase I of the cycle. These fasting bicarbonate and protein peaks reached, respectively, approximately 9 and 30% of the highest postprandial outputs and 4 and 14% of the maximal secretory capacity elicited by secretin or CCK. They were accompanied by a significant rise in plasma motilin, gastrin, and pancreatic polypeptide (PP), but only exogenous motilin given in physiological dose induced motility pattern and pancreatic secretion similar to those observed during phase III. Feeding interrupted both motor and secretory MMC cycle, increased the pancreatic secretion to approximately 40-60% of the maximal secretory capacity, and was accompanied by increments in plasma gastrin, cholecystokinin (CCK), secretin, and PP. None of these hormones applied alone in physiological dose was capable of reproducing the postprandial inhibition of MMC cycles. We conclude that the pancreatic secretion in fasted dogs fluctuates periodically in phase with duodenal motility, but the phase III peak secretory outputs represent only minute fractions of the maximal secretory capacity and can therefore be ignored in regular testing of pancreatic secretion.

Action Potentials↗
PubMed1986

Studies on the localization of secretin release from canine intestine.

In conscious dogs with chronic pancreatic fistulas, duodenal perfusion with HCl (16 mmol/h) stimulated pancreatic HCO-3 secretion to a similar degree as exogenous secretin (2 U/kg X h), while meat feeding (500 g) and duodenal perfusion with oleate (16 mmol/h) increased this secretion to about 58 and 43% of the highest response to secretin. Plasma secretin increments with duodenal HCl, feeding and duodenal oleate amounted to about 45, 13 and 8% of that achieved with secretin, producing the highest HCO-3 response. Perfusion of the in situ intestine with HCl at gradually increasing rates produced HCO-3 responses similar to those induced by exogenous secretin in graded doses, but the increments in plasma secretin with duodenal HCl were only about half those obtained with exogenous secretin, producing an equal rate of HCO-3 secretion. HCl perfusion of isolated Thiry loops made of the duodenojejunal portion also stimulated the HCO-3 secretion in a dose-dependent way, but raised plasma secretin only to about half that attained with secretin, producing a similar secretory rate. HCl in the proximal duodenal and distal jejunal loop slightly stimulated the HCO-3 secretion without affecting plasma secretin, and that in the ileal loop was without any effect on the pancreatic or plasma secretin. This study provides evidence that (a) endogenous secretin is released by feeding and duodenal perfusion with HCl and oleate, but only HCl appears to release sufficient amounts of secretin to drive the HCO-3 secretion, and (b) the release of secretin is confined mainly to the distal duodenum and proximal jejunum.

Animals↗
PubMed1986

Role of endogenous prostaglandins in duodenal alkaline response to luminal hydrochloric acid or arachidonic acid in conscious dogs.

Duodenal secretion of HCO-3 and luminal release of PGE2 were measured in conscious dogs. The results show that the HCO-3 secretion is closely correlated with the luminal release of PGE2 and that both the HCO-3 and the PGE2 outputs increase dose-dependently after topical application of hydrochloric acid or arachidonic acid. Indomethacin reduced basal HCO-3 and PGE2 release and prevented their increase in response to hydrochloric acid or arachidonic acid. We conclude that mucosal PGE2 plays an important role in the alkaline secretion from the duodenum.

Animals↗
PubMed1986

Cephalic phase of gastroduodenal alkaline secretion.

This study was designed to determine gastric alkaline secretion (GAS) and duodenal alkaline secretion (DAS) and their relation to the duodenal motility pattern in conscious dogs under basal conditions and after vagal stimulation by sham-feeding and insulin hypoglycaemia. GAS was measured in the gastric perfusate and DAS was determined in the perfusate of the upper duodenum (7 cm in length between occluding balloons). Resting GAS and DAS showed typical periodicity in phase with myoelectric and motor activity, reaching peaks during phases II and III, respectively, and nadir during phase I of the migrating motor cycle (MMC). Vagal excitation by sham-feeding or insulin hypoglycaemia resulted in an immediate rise in GAS and DAS, accompanied by a suppression of MMC. Atropine (25 micrograms/kg) reduced basal GAS and DAS by about 50% and abolished GAS but not DAS in response to vagal stimulation, being accompanied by complete suppression of MMC for several hours. Following injection of indomethacin (2.5 mg/kg) to suppress the generation of endogenous prostaglandins, a prolonged reduction in basal GAS and DAS and an increase in the myoelectric activity and the disruption of the MMC occurred. Neither GAS nor DAS responses to vagal stimulation were affected by indomethacin. We conclude that resting GAS and DAS fluctuate cyclically in phase with gastroduodenal motor activity, and that vagal excitation results in a potent stimulation of alkaline secretion and myoelectric activity which are, in part, cholinergic and do not depend upon the generation of endogenous prostaglandins.

Animals↗
PubMed1985

Gastrointestinal secretory, motor and circulatory effects of corticotropin releasing factor (CRF).

This study was designed to determine the effects of CRF on the gastrointestinal functions such as secretion, motility and circulation in dogs. CRF was found to inhibit dose-dependently gastric acid response to pentagastrin but not to histamine. CRF stimulated pancreatic bicarbonate and protein secretion under basal conditions and in response to secretin or cholecystokinin (CCK). This stimulation was accompanied by an increase in plasma levels of pancreatic polypeptide (PP), but not of secretin or gastrin. CRF caused a partial inhibition of the migrating motor complexes in fasted dogs and increased spike activity of the small bowel. These motor effects of CRF probably resulted from the action of the released PP on the intestinal smooth muscle. CRF is also a potent and selective stimulant of the mesenteric blood flow. This effect may be secondary to the stimulation of intestinal motility and metabolism.

Action Potentials↗
PubMed1985

Gut hormones in stimulation of gastroduodenal alkaline secretion in conscious dogs.

Alkaline secretion from the fundic and antral pouches of the stomach and the loops of proximal and distal duodenum was measured in conscious dogs under basal conditions and after intragastric instillation of HCl solution, meat feeding, or intravenous infusion of various gut hormones. In control tests on fasted dogs HCO-3 output from the duodenal mucosa was severalfold higher than that from the gastric mucosa. Instillation of 10 mM HCl into the stomach resulted in a significant increment in HCO-3 secretion from the gastric pouches and proximal duodenal loops, and this was accompanied by a marked increase in plasma secretin, cholecystokinin (CCK), and pancreatic polypeptide (PP) levels. Meat feeding stimulated HCO-3 secretion from proximal duodenum, and it was accompanied by a significant elevation in plasma gastrin, secretin, CCK, gastric inhibitory peptide, and PP. Among exogenous hormones, the most effective stimulant of HCO-3 secretion was PP, which caused a significant increase in HCO-3 output from the gastric and duodenal mucosa at doses (125-500 pmol X kg-1 X h-1) that raised plasma PP to postprandial levels. CCK in physiological doses (21-85 pmol.kg-.h-1) also stimulated HCO-3 secretion from gastric pouches and proximal duodenal loops. Neurotensin stimulated HCO-3 secretion from both gastric pouches and duodenal loops. In contrast, gastrin or secretin did not affect significantly HCO-3 secretion from the gastroduodenal mucosa. This study provides evidence that some gut hormones, particularly PP, CCK, and neurotensin, may be involved in the physiological stimulation of gastroduodenal alkaline secretion.

Animals↗
PubMed1985

Effects of cyclic hexapeptide analog of somatostatin on pancreatic secretion in dogs.

The effects of a cyclic hexapeptide analog of somatostatin, [cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe)] (cyclo-SS), administered intravenously (iv) or instilled into the duodenum (id) on the pancreatic response to endogenous (meal and duodenal acidification) and exogenous (secretin, CCK) stimulants were compared in five dogs with esophageal, gastric, and pancreatic fistulae. Cyclo-SS given iv in graded doses against a constant background stimulation with secretin caused a similar and dose-dependent inhibition of pancreatic HCO3 and protein secretion being about twice as potent as somatostatin-14 (SS-14). Cyclo-SS, whether applied topically to the duodenal mucosa in a dose of 1 microgram/kg or given iv at a dose of 0.5 microgram/kg-hr, resulted in a similar inhibition of pancreatic secretion induced by feeding a meat meal, sham-feeding, duodenal acidification, or infusion of secretin or CCK. The inhibition of pancreatic secretion by cyclo-SS was due in part to direct inhibitory action on the exocrine pancreas as well as to the suppression of the release of secretin, insulin, and pancreatic polypeptide. It is concluded that cyclo-SS is a more potent inhibitor of pancreatic secretion than SS-14 and that it is active when administered both parenterally and intraduodenally.

Animals↗
PubMed1984

Gastroduodenal alkaline response to acid and taurocholate in conscious dogs.

Alkaline secretion was measured in the fundic and antral portions of the stomach and in the upper and distal portions of the duodenum in conscious dogs under basal conditions, in response to luminal exposure of HCl and taurocholate, and after feeding. Topical application of HCl (6.7-100 mM) resulted in an increase in HCO-3 output, particularly from the upper duodenum, and this was associated with the rise in prostaglandin (PG) E2 release. Since both these effects were abolished by pretreatment with indomethacin, it was concluded that the stimulation of alkaline secretion by topical HCl is mediated by mucosal PGs. HCl instilled into the main stomach or feeding a meat meal also caused an increase in alkaline secretion from the isolated (non-acid-perfused) gastric and duodenal portions, but this effect was not affected by indomethacin, suggesting that it was not mediated by endogenous PGs. Direct exposure of the mucosa to luminal taurocholate (0.62-20 mM) adjusted to pH 6.0 also increased gastroduodenal HCO-3 output, but this effect was not affected by indomethacin and accompanied by a fall in transmucosal PD value, suggesting that it could be due to the damage of the mucosa and increased mucosal permeability to HCO-3. We conclude that gastroduodenal HCO-3 output increases in response to natural substances such as HCl, taurocholate, or feeding, and the mechanism of this increase differs depending on the stimulant used.

Animals↗
PubMed1984

Role of prostaglandins in alkaline secretion from the gastroduodenal mucosa exposed to acid and taurocholate.

Gastroduodenal mucosa produces alkaline secretion (AS) that is several times greater in the duodenum, particularly in its proximal part, than in the fundic or antral portions of the stomach. Exogenous prostaglandins (PGs) of E and F but not of I series are capable of augmenting AS. Similar stimulatory effects on AS were observed after topical administration of arachidonic acid and HCl solution. Endogenous PGs appear to mediate this AS as their release from the mucosa is increased upon exposure to arachidonic acid and the pretreatment with indomethacin reduced the alkaline response to arachidonic acid and HCl. Taurocholate-induced alkaline response is probably due to increased mucosal permeation for HCO3 as it was accompanied by a decrease in PD value and indomethacin failed to affect this response.

16,16-Dimethylprostaglandin E2↗
PubMed1984

Effects of omeprazole, a substituted benzimidazole, on gastrointestinal secretions, serum gastrin, and gastric mucosal blood flow in dogs.

In dogs with gastric fistulas and vagally denervated Heidenhain pouches, omeprazole, a benzimidazole derivative infused intravenously or given intraduodenally, dose-dependently inhibited gastric acid secretion, which had been induced by histamine, pentagastrin, or urecholine. It also suppressed gastric acid response to physiologic stimulants such as sham-feeding and gastric peptone meal without affecting serum gastrin level. The inhibition of histamine-induced acid secretion was accompanied by a parallel reduction in the mucosal blood flow, but no significant alteration in the ratio (R) value, indicating that omeprazole primarily affected gastric acid secretion but did not limit gastric mucosal microcirculation. Omeprazole, infused into the Heidenhain pouch, caused a dose-dependent inhibition of the Heidenhain pouch response to intravenous histamine without any significant change in the acid response of the main stomach and plasma concentrations of the drug. This indicates that omeprazole may exhibit local inhibitory action on the oxyntic glands. Omeprazole did not affect gastric mucosal integrity or the rate of alkaline secretion from the gastroduodenal mucosa or the pancreas stimulated by duodenal acidification or secretin.

Administration, Topical↗
PubMed1983

Prostaglandins and alkaline secretion from oxyntic, antral, and duodenal mucosa of the dog.

Alkaline secretion (AS) measured under basal conditions in oxyntic and antral pouches of conscious dogs averaged about 20 mumol/30 min and was about three times lower than that from the duodenal pouch. Natural prostaglandin E2 and prostaglandin F2 alpha, but not prostaglandin I2, were effective stimulants of AS, mainly when given topically. Stable analogues such as 16,16-dimethyl prostaglandin E2 and prostaglandin I2 were relatively more potent stimulants than their parent prostaglandins (PGs), particularly when applied topically. The highest alkaline response of the oxyntic pouch to PG was about 5% of the maximal acid response of this pouch to histamine. Indomethacin reduced markedly AS from the duodenal but not from the oxyntic or antral pouch. AS from the duodenal pouch was relatively more sensitive than that from gastric pouches to the stimulation by PGs, which were effective also after pretreatment with indomethacin. This study shows that the oxyntic, antral, and duodenal mucosa of conscious dogs is capable of secreting bicarbonate, and this secretion, particularly from the duodenal mucosa, is highly sensitive to the stimulation with certain PGs, mainly of the E and F type and their analogues, and to suppression by indomethacin, a potent inhibitor of PG biosynthesis, suggesting that endogenous PGs are involved in the mechanism of AS.

Animals↗
PubMedDate not supplied

Effects of human corticotropin releasing factor (CRF) on gastric and pancreatic secretion in vivo and in vitro.

Human CRF given IV inhibited dose-dependently pentagastrin- but not histamine-induced gastric acid secretion. When added to the incubation medium of the isolated gastric glands, CRF did not alter the formation of HCl under basal conditions or after stimulation with histamine or DBcAMP. CRF caused a small but significant increase in pancreatic HCO3 and protein secretion. It augmented CCK-induced pancreatic protein and secretin-induced HCO3 secretion in vivo but failed to affect basal or stimulated (CCK and urecholine) amylase release by the in vitro dispersed pancreatic acini. This study indicates that CRF inhibits gastric and stimulates pancreatic secretion in vivo but not in vitro and these effects are indirect involving, at least in part, alterations in the pancreatic circulation.

Animals↗